BeiGene’s BRUKINSA gains accelerated FDA approval for follicular lymphoma treatment

In a significant development for patients with relapsed or refractory follicular lymphoma, BeiGene, Ltd. has announced the U.S. Food and Drug Administration (FDA) has granted ... Read More